Beeline Medicines launched with five programs licensed from Bristol Myers Squibb and secured a $300 million Series A led by Bain Capital. Its lead asset, afimetoran, is a once-daily oral selective TLR7/8 inhibitor for lupus, supported by clinical proof-of-concept in cutaneous lupus erythematosus and Fast Track designation for systemic lupus erythematosus. The startup will be responsible for ongoing and future development under transition points for BMS legacy trials, while expanding the portfolio with immunology programs including an IL-2-CD25 fusion protein aimed at regulatory T cells, a TYK2 inhibitor for rare immune diseases, and additional biologics targeting IL-18 and IL-10. For the biotech ecosystem, the move illustrates how Big Pharma licensing can fund focused modality execution—particularly in inflammation—once a sponsor’s trial ownership and transition strategy is defined.